Thermo Fisher Scientific (NYSE:TMO) has completed technology transfer and product introduction for Ibtrozi, a treatment for ...

Matthew Herper covers medical innovation — both its promise and its perils. The biotech firm Nuvalent said Tuesday that new data indicate its targeted drug zidesamtinib could help patients with a rare ...

Thermo Fisher Scientific, the world leader in serving science, will now manufacture drug product for Nuvation Bio in the ...

Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 Best Penny Stocks to Buy Before They Explode. On May 6, 2026, Nuvation Bio Inc ...

The FDA approved taletrectinib (Ibtrozi)-- a next-generation oral ROS1 tyrosine kinase inhibitor (TKI) -- for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell ...

NEW YORK--(BUSINESS WIRE)--AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced positive ...

ROS1 may be a rare mutation in the cancer world, but a group of ROS1 patients have taken it upon themselves to search for answers. There's an old saying in medicine, "When you hear hoof beats, think ...

Targeted cancer drugs are widely used because of their ability to inhibit specific proteins involved in cancer development with fewer side effects compared to chemotherapy drugs. But targeted ...

Ibtrozi (taletrectinib) is approved for ROS1-positive NSCLC, showing high efficacy in TRUST-I and TRUST-II trials. Treatment-naive patients had response rates of 90% and 85%, with significant duration ...

The ROS-1 NSCLC current market is mainly dominated by tyrosine kinase inhibitors such as XALKORI at present and is anticipated to be dominated by Repotrectinib, Taletrectinib, and NVL-520 by 2034.

"As with ALK-positive lung cancer, ROS1-positive lung cancer defines a distinct subset of patients for whom crizotinib is efficacious." The approval is based on a multicenter, single-arm Phase 1 study ...

Barcelona, Spain: Preliminary data from a phase I clinical trial of a new drug called NVL-520 for patients with non-small cell lung cancer (NSCLC) and other solid tumours, suggest that it may have the ...